Deca-Durabolin 50 mg/ml Solution for InjectionNandrolonealso known deca durabolin definition nortestosteroneis an androgen and anabolic steroid AAS which is used in the form deca durabolin definition esters such as nandrolone decanoate brand name Deca-Durabolin and nandrolone phenylpropionate brand name Durabolin. Side effects of nandrolone esters include symptoms of masculinization like acneincreased hair growthvoice changesand increased sexual desire. Nandrolone esters were first described and introduced for medical use in the late deca durabolin definition. Nandrolone esters are used clinically, although increasingly rarely, for people in catabolic states with definigion burns, durabllin, and Dwfinition, and an ophthalmological formulation was available to support cornea healing. The positive effects of nandrolone esters include muscle growth, appetite stimulation and increased red blood cell production, [ medical citation needed ] and bone density. Nandrolone sulfate has been used in an eye drop formulation as an ophthalmic medication. Nandrolone esters are different types of anabolic steroids explained for physique- and performance-enhancing purposes by competitive athletesbodybuildersand powerlifters.
Deca Durabolin | definition of Deca Durabolin by Medical dictionary
Pharmaceutical form Solution for injection Clear, yellow, oily solution 4. We would recommend that the effectiveness of therapy be monitored with the appropriate methods for osteoporosis on a monthly basis. Deca-Durabolin should be administered by deep intramuscular injection 4.
Breast-feeding Porphyria Hypersensitivity to the active substance or to any of the excipients, including arachis oil. Deca-Durabolin is therefore contraindicated in patients allergic to peanuts or soya see section 4. Physicians should consider monitoring patients receiving Deca-Durabolin before the start of treatment, at quarterly intervals for the first 12 months and yearly thereafter for the following parameters: Conditions that need supervision: Patients, especially the elderly, with the following conditions should be monitored for: In these patients hypercalcaemia or hypercalciuria may develop spontaneously, and also during androgen therapy.
Nevertheless, the hypercalcaemia or hypercalciuria should first be treated appropriately and after restoration of normal calcium levels, if judged necessary and taking into account the risks and benefits on a case by case basis, hormone therapy can be resumed, with caution. In such cases treatment must be stopped immediately. Patients who experienced myocardial infarction, cardiac-, hepatic- or renal insufficiency, hypertension, epilepsy, or migraine should be monitored due to the risk of deterioration of or reoccurrence of disease.
If anabolic steroid-associated adverse reactions occur see section 4. Patients should be informed about the potential occurrence of signs of virilisation. In particular, singers and women with speech professions should be informed about the risk of deepening of the voice. Mis use in sports: The misuse of Nandrolone and other anabolic steroids to enhance ability in sports carries serious health risks and is to be discouraged.
As there is a possible relationship between allergy to peanut and allergy to soya, patients with soya allergy should also avoid Deca-Durabolin see section 4. Benzyl alcohol may cause anaphylactoid reactions in infants and children up to 3 years old. Safety and efficacy have not been adequately determined in children and adolescents. In pre-pubertal children statural growth and sexual development should be monitored since anabolic steroids in general and Deca-Durabolin in high dosages may accelerate epiphyseal closure and sexual maturation.
Therefore, adjustment of the dose of Deca-Durabolin may be required. Insulin and other anti-diabetic medicines: Anabolic steroids may improve glucose tolerance and decrease the need for insulin or other anti-diabetic drugs in diabetic patients see section 4. Patients with diabetes mellitus should therefore be monitored especially at the beginning or end of treatment and at periodic intervals during Deca-Durabolin treatment.
High doses of Deca-Durabolin may enhance the anti-coagulant action of coumarin- type agents see section 4. Therefore close monitoring of prothrombin time and if necessary a dose reduction of the anti-coagulant is required during therapy. The concurrent administration of anabolic steroids with ACTH or corticosteroids may enhance edema formations; thus these active substances should be administered cautiously, particularly in patients with cardiac or hepatic disease or in patient predisposed to edema see section 4.
Anabolic steroids may decrease levels of thyroxine-binding globulin resulting in decreased total T4 serum levels and increases resin uptake of T3 and T4. Free thyroid hormone levels remain unchanged, however, and there is no clinical evidence of thyroid dysfunction.
Combination of Deca-Durabolin with rhEPO recombinant human erythropoietin , especially in females, may enable a reduction of the erythropoietin dose to reduce anemia. Pregnancy There are no adequate data for the use of Deca-Durabolin in pregnant women.
In view of the risk of virilisation of the foetus, Deca-Durabolin should not be used during pregnancy. Treatment with Deca-Durabolin should be discontinued when pregnancy occurs. There are no adequate data for the use of this medicine during lactation to assess potential harm to the infant or a possible influence on milk production. Therefore, Deca-Durabolin should not be used during lactation. In men treatment with Deca-Durabolin can lead to fertility disorders by repressing sperm-formation.
In women treatment with androgens can lead to an infrequent or repressed menstrual cycle see section 4. Injectables in general, may cause local reaction at the injection site. Deca-Durabolin at the recommended dosages is unlikely to produce virilising effects. Virilisation which appears in sensitive women as hoarseness, acne, hirsutism and increase of libido. Hoarseness may be the first symptom of vocal change which may end in long-lasting, sometimes irreversible deepening of the voice.
The terms used to describe the undesirable effects above are also meant to include synonyms and related terms. There are no reports of acute overdosage with Deca-Durabolin in the human.
A14A B01 Nandrolone is chemically related to testosterone and shows enhanced anabolic and a reduced androgenic activity. In humans Deca-Durabolin has been shown to positively influence calcium metabolism and to increase bone mass in osteoporosis. Nandrolone lacks the C17 alpha-alkyl group which is associated with the occurrence of liver dysfunction and cholestasis.
Nandrolone decanoate is slowly released from the injection site into the blood with a half-life of 6 days. The ester is rapidly hydrolysed to nandrolone in the blood with a half-life of one hour or less. The half-life for the combined process of hydrolysis of nandrolone decanoate and of distribution and elimination of nandrolone is 4. Nandrolone is metabolised by the liver.
It is not known whether these metabolites display a pharmacological action. No formal studies to assess reproduction toxicity, genotoxicity and carcinogenicity have been conducted by the company. The use of androgens in different species has resulted in virilisation of the external genitals of female foetuses. Investigations into the genotoxic potential of nandrolone showed it to be positive in an in vitro micronucleus assay and an in vivo micronucleus assay in mouse but not rat, and in the comet assay of mouse and rat.
Continue typing to refine. Back to top Aspen contact details. Active ingredient nandrolone decanoate. Last updated on eMC: Show table of contents Hide table of contents 1. Name of the medicinal product 2. Qualitative and quantitative composition 3. Marketing authorisation holder 8. Marketing authorisation number s 9. Date of revision of the text. This information is intended for use by health professionals. Solution for injection Clear, yellow, oily solution.
For use in osteoporosis in post-menopausal women Established osteoporosis should have been diagnosed by the following parameters: Post-menopausal women 50mg every three weeks The duration of treatment depends on the clinical response and the possible occurrence of side-effects. Deca-Durabolin should be administered by deep intramuscular injection. Pregnancy see section 4. Enzyme-inducing agents may decrease and enzyme-inhibiting drugs may increase nandrolone levels.
Deca-Durabolin is contra-indicated in women who are pregnant see section 4. Deca-Durabolin has no influence on the ability to drive and use machines. Due to the nature of Deca-Durabolin, side effects cannot be quickly reversed by discontinuing medication.
The acute toxicity of nandrolone decanoate in animals is very low. Absorption Nandrolone decanoate is slowly released from the injection site into the blood with a half-life of 6 days. Distribution The ester is rapidly hydrolysed to nandrolone in the blood with a half-life of one hour or less. Biotransformation and excretion Nandrolone is metabolised by the liver. Toxicity studies in animals after repeated dosing did not indicate a safety risk for humans.
Company contact details Aspen. To bookmark a medicine you must be a registered user. To email a medicine you must be a registered user. Find out more here. Respiratory, thoracic and mediastinal disorders. Hepatic function abnormal Peliosis hepatis Liver tumours. General disorders and administration site conditions.
Oedema Injection site reaction Sodium retention.